ARTICLES BY LOUIS

• Sanofi Pasteur: Vaccine Ecosystem In Danger

  5/12/2015

  The intent was to investigate outsourcing in the innovative vaccine industry. However, it became obvious we’d first need to decipher a Kafkaesque world of organizations and markets. “There are strong warning signs out there,” says Michael Watson, VP of Global Immunization Policy, Sanofi Pasteur.

• Adare Pharmaceuticals Business Model Steady Through the Rodeo

  5/5/2015

  Here's a partnering business-model well-suited to the dug development strategies of biotechnology and pharmaceutical companies, as well as the court of public opinion.

• Not a Sterile Debate On Aseptic Services Crunch

  5/4/2015

  Driving the aseptic services sector is positive news, but with a side effect: the breakthroughs in biologics and other increasingly complex products are enabling the creation of exciting new drugs and therapies … but all requiring the “right” capacity and “perfect" compliance at aseptic facilities.

• Amgen Three-Deep With Suppliers; Lilly “Making Medicine Together”

  4/17/2015

  Bill Rich, VP, External Supply, Amgen, says pharma is duty-bound to monitor the supply chain down to “our suppliers’ suppliers’ suppliers.” For his part, Craig Michael, Director External API Manufacturing, Eli Lilly and Company, says the whole supply chain needs to say, believe and act as, "I make medicine."

• Pharma's New Partner At Regulatory and Legislative Tables

  4/13/2015

  Pharma should take this organization as a sign the CMO/CDMO industry is maturing. It’s taking itself seriously, and moving forward as an important sector of the healthcare industry.

• Gilead Saves Lives And Healthcare Dollars By Taking Profits

  4/6/2015

  It’s affordable worldwide, saves lives and healthcare dollars, allows a company to create more innovative drugs, and validates the biotech business model. Why a negative bias?

• Outsourcing Industry Awarded A Home

  3/31/2015

  Biopharma companies celebrating the CMO Awards with providers form deeper relationships, increased productivity, and the best outcomes from outsourcing activities. 

• 7 CEOs Say It's About The “Bios”: Biotechs, Biopharmaceuticals and Biosimilars

  3/9/2015

  The booming “Bios” are spurring expenditures, supply-and-demand questions and business decisions, and grabbing the attention of CEOs in 2015. 

• 7 CEOs Say Outsourcing Advancing … On Swirling Currents (Part 1)

  3/3/2015

  How’s it going in the global BioPharma outsourcing industry? I reached out to 7 CEOs at global CROs/CDMOs for trends from the trenches  – or at least the frontlines. 

• Biopharma Looks Into The Supply Chain Mirror: We're The Problem

  2/26/2015

  It’s like a scene from a Brothers Grimm folk tale. One late afternoon at an industry conference, a cross section of biopharmaceutical leaders gather in a room to take a hard look into a large mirror. It reflects that they — not their suppliers or service providers, as was assumed — are culpable for, and thus can control, many of the product reliability problems in their supply chains.